Jazz Pharma to Pay $145 Million to Settle Narcolepsy Drug Antitrust Case
Insurance Journal - Apr 09, 2025
Jazz Pharmaceuticals JAZZ.O said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in the U.S., is used for the …...
Recommended Articles
Posted: Apr 16, 2026
The medical officer for the Texas summer camp where 27 girls were killed in a flood last year testif...
Posted: Apr 16, 2026
Utah-based insurance broker Trucordia reports it has acquired the Paradiso Financial and Insurance S...
Posted: Apr 16, 2026
Inszone Insurance Services announced the acquisition of Insurance Resources Group, Inc. Located in O...